26
September 2024
Incanthera
plc
("Incanthera" the
"Company")
Commercial
Update
Skin + CELL Initial Launch
Extended Across Europe
Incanthera plc (AQSE:INC), the
company focused on innovative technologies in dermatology and
oncology, announces an update regarding the forthcoming launch of
Skin + CELL, its luxury skincare range.
On 11 July 2024, the Company
announced that the initial launch of Skin + CELL would take place
in approximately 60 of Marionnaud's stores in Switzerland and
Austria, in September 2024, with a larger pan-European rollout to
occur at a later date.
Following recent discussions and
meetings with Marionnaud and AS Watson Group, the initial launch
of Skin + CELL, the
Company's luxury skincare brand range, is now
planned to be expanded from the originally expected launch, to a
broader product launch across the European retail network sooner
than expected.
Marionnaud's European network
totals 1,200 stores in 11 European
countries.
The timing of this broader product
launch is currently in discussion with Marionnaud and AS Watson
Group and the Company will update the market further about this in
October.
Incanthera's Skin + CELL initial
launch production order, together with previously advised
additional production orders, totalling 350,000 units, will now be
used for the wider European roll out for anticipated orders before
the Company's current financial year to 31 March 2025. This
re-affirms management's projected revenues for the financial year
to exceed £10 million and for Incanthera to achieve
profitability.
Alongside the significantly enhanced
launch of our product range across Europe, discussions with
Marionnaud and AS Watson Group also involve new product initiatives
for introduction beyond this initial roll out.
We look forward to updating the
market further on these details as our plans progress.
Commenting, Chairman, Tim McCarthy,
said:
"Our partnership with Marionnaud and the broader AS Watson
Group continues in strength, clearly demonstrated by their
confidence in the broadening of the initial launch into the wider
European network.
Our ongoing discussions as an exclusive supplier of luxury
functional skincare within their retail network, and the potential
for new product initiatives, shows the enormous opportunity in the
Skin + CELL brand across the AS Watson
Group."
For further information please
contact:
Notes to Editors
About Incanthera plc
Incanthera is a specialist company
focused on innovative technologies in dermatology and
oncology. It seeks to identify and develop innovative solutions to
current clinical, commercially relevant unmet needs, utilising new
technology from leading specialists and academic institutions as
well as its in-house development team.
The Company originated from
the Institute of Cancer Therapeutics ("ICT") at
the University of Bradford. Incanthera's strategy
is to develop each candidate in its portfolio from initial
acquisition or discovery to securing its future through
commercially valuable partnerships at the earliest opportunity in
its development pathway.
For more information on the Company
please visit: www.incanthera.com
@incantheraplc
About Skin + CELL
Skin + CELL is Incanthera's luxury
skincare brand utilising our ground-breaking formulation and
delivery expertise, to bring scientifically proven formulations to
cosmetics. Skin + CELL's unique formulations, enriched with
targeted bioactive B3 (an activated form of niacinamide) are other
ingredients are delivered directly into the skin's cells to
optimise and protect cellular health, energy and protective
capabilities.
Incanthera's new bioactive skincare
technology harnesses unique delivery pathways through recently
patented formulations designed by our in-house experts who have
previously formulated skincare for some of the world's leading
skincare and pharmaceutical companies. These formulations fortify
otherwise depleted physiological pathways to improve the skin's
performance, ability to self-repair and to address previously unmet
cosmetic conditions in skin health.
•
Skin + CELL's unique formulations, currently
enriched with targeted bioactive B3 (an activated form of
niacinamide) but anticipating further bioactive ingredient
formulations are delivered directly into the skin's cells to
optimise cellular health, energy and protective
capabilities.
•
Independent studies have shown Incanthera's
technology is uniquely effective in delivering Bioactive B3 into
the skin, energising the living cells of the skin to maintain
natural health and protection against adverse environmental
challenges and maintaining even skin tones.
•
Skin + CELL's complementary range of products are
based on advanced, clinically designed, formulation concentrates
which combine leading edge pharmaceutical enhancement technology
with selected prestige cosmetic ingredients to give an effective
product which gives a silky emollience in use and leaves the skin
visibly radiant, energised and protected.
Skin + CELL's luxury skincare
current range extends across face, body, hand, face serum and eye
cream, and will also include bioactive SPF concentrations and
further derivatives of vitamins in the future.
About Marionnaud
Marionnaud is the largest luxury
perfumery and cosmetics chain in Europe with over 1,220 stores and
a 27% market share in France. Marionnaud is managed by the AS
Watson Group based in Hong Kong, the world's largest international
health and beauty retailer.
https://www.marionnaud.com
About A.S. Watson
The A.S. Watson Group is the
world's largest international health and beauty retailer, with
16,100 stores in 28 markets, primarily in Asia and Europe. A
member of CK Hutchison Holdings, A.S. Watson operates the world's
largest portfolio of retail formats, retail brands and has the
largest geographical presence including a significant online retail
presence.
http://www.aswatson.com/
https://youtu.be/IZ6TolZi4Go
Forward looking statement disclaimer
Certain statements made in this
announcement are forward-looking statements. These forward-looking
statements are not historical facts but rather are based on the
Company's current expectations, estimates, and projections about
its industry; its beliefs; and assumptions. Words such as
'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,'
'estimates,' and similar expressions are intended to identify
forward-looking statements. These statements are not guarantees of
future performance and are subject to known and unknown risks,
uncertainties, and other factors, some of which are beyond the
Company's control, are difficult to predict, and could cause actual
results to differ materially from those expressed or forecasted in
the forward-looking statements. The Company cautions shareholders
and prospective shareholder holders not to place undue reliance on
these forward-looking statements, which reflect the view of the
Company only as of the date of this announcement. The
forward-looking statements made in this announcement relate only to
events as of the date on which the statements are made. The Company
will not undertake any obligation to release publicly any revisions
or updates to these forward-looking statements to reflect events,
circumstances, or unanticipated events occurring after the date of
this announcement except as required by law or by any appropriate
regulatory authority.